Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-10-20

FDA Approved: SKYTROFA — Supplemental Application (Ascendis Pharma Endocrinology, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for SKYTROFA (lonapegsomatropin-tcgD) from Ascendis Pharma Endocrinology, Inc., indicating an update to its labeling…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Skytrofa (lonapegsomatropin)

Snippet

SUPPL AP for SKYTROFA (LONAPEGSOMATROPIN-TCGD)